AKTIENANLEIHE - ROCHE GS Stock

Certificat

DE000VU655U9

Market Closed - Deutsche Boerse AG 02:04:44 2024-05-17 pm EDT
69.82 EUR +0.87% Intraday chart for AKTIENANLEIHE - ROCHE GS
Current month+5.40%
1 month+4.51%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-17 69.82 +0.87%
24-05-16 69.22 +2.91%
24-05-15 67.26 +1.19%
24-05-14 66.47 -1.09%
24-05-13 67.2 +0.60%

Delayed Quote Deutsche Boerse AG

Last update May 17, 2024 at 02:04 pm EDT

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU655U
ISINDE000VU655U9
Date issued 2023-05-10
Strike 350 CHF
Maturity 2024-06-21 (34 Days)
Parity 0.35 : 1
Emission price 100
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 102.7
Lowest since issue 63.99

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW